COMPASS Pathways plc (CMPS)
Market Cap | 455.57M |
Revenue (ttm) | n/a |
Net Income (ttm) | -86.23M |
Shares Out | 42.58M |
EPS (ttm) | -2.05 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 287,639 |
Open | 10.83 |
Previous Close | 10.72 |
Day's Range | 10.64 - 10.92 |
52-Week Range | 6.54 - 21.50 |
Beta | 2.29 |
Analysts | Buy |
Price Target | 46.83 (+337.66%) |
Earnings Date | Feb 23, 2023 |
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Ki... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $46.83, which is an increase of 337.66% from the latest price.
News

All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II...

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ...

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?
COMPASS Pathways PLC Sponsored ADR (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ...

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ann...

Compass Pathways (CMPS): The McDonald's of Psychedelics?
This week, we're talking about my Big Three investing themes for the rest of the year (and beyond). You've probably heard me talk about each at one point or another.

COMPASS Pathways to participate in three upcoming investor events
LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ann...

7 Psychedelics Stocks to Buy for a Big Drug Boom
Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and...

One Mind Announces the Winners of the 2022 Rising Star Awards for Mental Health Research
RUTHERFORD, Calif.--(BUSINESS WIRE)--One Mind, in collaboration with COMPASS Pathways plc, has announced the recipients of three “2022 One Mind – COMPASS Rising Stars Awards."

3 Best Psychedelic Stocks to Buy Now
The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.

Wall Street Analysts See a 289% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
The consensus price target hints at a 288.6% upside potential for COMPASS Pathways PLC Sponsored ADR (CMPS). While empirical research shows that this sought-after metric is hardly effective, an upward...

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ...

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacologic...

COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, anno...

Dear Psychedelic Stocks Fans, Watch This Key Catalyst
Psychedelic stocks are in focus following new legislation from both the Senate and the House that has bipartisan support. The post Dear Psychedelic Stocks Fans, Watch This Key Catalyst appeared first ...

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
Kabir Nath will build upon COMPASS' success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care

Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric...

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression